Therapeutic Strategies With Selective CDK4/6 Inhibitors: An Oncologist’s Guide to Safe Inhibition of Uncontrolled Cellular Proliferation in Solid Tumors

Review recent developments with selective CDK4/6 inhibitors in the care of patients with various cancers in this text module on-demand Webcast and accompanying slideset developed by Richard Finn MD Geoffrey Shapiro MD PhD and Gary K. Schwartz MD.

Share

Program Content

Activities

Downloadable Slideset
Selective CDK4/6 Inhibitors in Cancer: Moving Beyond Breast Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: April 14, 2017

Expires: April 13, 2018

Targeting CDK4/6
Targeting CDK4/6 in Patients With Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2017

Expires: June 07, 2018

CDK4/6 Inhibitors: Activity and Resistance
Clinical Development of Selective CDK4/6 Inhibitors: Monotherapy Activity and Mechanisms of Resistance
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2017

Expires: June 07, 2018

CDK4/6 Inhibitor Combinations
Combination Approaches and Extending the Use of CDK4/6 Inhibitors Beyond ER-Positive Breast Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2017

Expires: June 07, 2018

Activities

CDK4/6 Inhibitors in Cancer Care
Selective CDK4/6 Inhibitors: A New Paradigm With Expanding Application in Cancer Care
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: July 13, 2017

Expires: July 12, 2018

Faculty

cover img faculity

Richard S. Finn, MD

Assistant Professor of Medicine
Division of Hematology-Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

cover img faculity

Gary K. Schwartz, MD

Professor of Medicine
Department of Medicine
Columbia University
Chief, Division of Hematology and Oncology
Department of Medicine
Columbia University Medical Center
New York, New York

cover img faculity

Geoffrey Shapiro, MD, PhD

Associate Professor
Department of Medicine
Harvard Medical School
Director, Early Drug Development Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Pfizer, Inc.